Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Florida Gets 36% Raise From Pfizer Under New Disease Management Contract

Executive Summary

Pfizer's contract extension with Florida provides a 36% increase in savings from disease management programs over the previous agreement
Advertisement

Related Content

Pfizer And Lockheed Martin Will Test Disease Management Program
Neurontin Off-Label Use Needs Prior Authorization Under Fla. Medicaid Plan
Medicare Rx Winners May Be Determined By Formulary, Policy-Savvy
Pfizer “Evolves” From Rx To Health Care Company: Fla. Medicaid Is Blueprint
Rx Leaflets: Merck, Pfizer Want FDA To Encourage Use Of Manufacturer Info
Florida Disease Management Report: Programs Save 11%; Rebates Save More
Pfizer Florida Medicaid Accounting Will Be Ready In March; Is Texas Next?
Bristol Follows Pfizer Formula For Access To Florida Medicaid
Pfizer Florida Formula: Free Goods In Exchange For Formulary Status
Pfizer Florida Formula: Free Goods In Exchange For Formulary Status
Advertisement
UsernamePublicRestriction

Register

PS042533

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel